Nonablative stem cell transplantation for older patients with acute leukemias and myelodysplastic syndromes.

Abstract:

:High-dose chemoradiotherapy with allogeneic bone marrow or peripheral blood stem cell transplantation (SCT) is a potentially curative treatment for advanced or poor-prognosis hematological malignancies. This procedure was initially considered as a means to deliver supralethal doses of chemotherapy and radiation for the eradication of the malignancy, but it has subsequently become apparent that much of the therapeutic benefit of SCT relates to an associated immune-mediated graft-versus-leukemia (GVL) effect. Additionally, due to the increased risk of morbidity and graft-versus-host disease (GVHD) that occurs with advanced age, the use of standard myeloablative preparative regimens with allogeneic progenitor cell transplantation has been generally limited to younger patients in good medical condition. However, most patients with hematologic malignancies are older and therefore the overall impact of allografting is relatively small. Thus despite resulting in high rates of long term disease control, allografting is only performed in a small fraction of patients, either because of lack of a suitable donor or the high risk of toxicity due to age or the general medical condition. Therefore strategies aimed at improving the safety and tolerability of allografting to allow for its more frequent application in older patients are necessary.

journal_name

Semin Hematol

journal_title

Seminars in hematology

authors

Giralt S,Anagnostopoulos A,Shahjahan M,Champlin R

doi

10.1053/shem.2002.30909

subject

Has Abstract

pub_date

2002-01-01 00:00:00

pages

57-62

issue

1

eissn

0037-1963

issn

1532-8686

pii

S003719630250007X

journal_volume

39

pub_type

杂志文章,评审
  • Novel agents in development for peripheral T-cell lymphoma.

    abstract::Though peripheral T-cell lymphoma (PTCL) is an area of significant unmet therapeutic need, a number of new treatment options are available for patients, especially those with relapsed or refractory disease. A plethora of drugs are now in development for PTCL, but drugs that truly target novel disease biology are notic...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2010.01.014

    authors: O'Connor OA

    更新日期:2010-04-01 00:00:00

  • Pentostatin for the treatment of indolent lymphoproliferative disorders.

    abstract::Purine analogues have been shown to be active in a variety of B- and T-cell malignancies. Among them, pentostatin is also a tight binding inhibitor of adenosine deaminase (ADA), a key enzyme of purine metabolism. ADA is present in all human tissues, with the highest levels in the lymphoid system. Early clinical trials...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2005.12.005

    authors: Ho AD,Hensel M

    更新日期:2006-04-01 00:00:00

  • Mismatched unrelated alternative donors for hematological malignancies.

    abstract::For the majority of hematologic malignancies allogeneic hematopoietic cell transplantation (HCT) is the only curative treatment option. Sibling donors have been the standard for adult patients. Since there is not a suitable family donor for all patients, the need for alternative donors for HCT is great. Fortunately, t...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2016.01.009

    authors: Sebastian Schäfer H,Finke J

    更新日期:2016-04-01 00:00:00

  • Autologous hematopoietic cell transplantation for AML in first remission - An abandoned practice or promising approach?

    abstract::Patients with acute myeloid leukemia (AML) who achieve complete remission after induction therapy require post remission therapy (PRT) in order to remain disease free. The role of autologous hematopoietic cell transplantation (autoHCT) in the PRT setting is controversial and is largely based on older trials that were ...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2019.01.001

    authors: Yeshurun M,Wolach O

    更新日期:2019-04-01 00:00:00

  • Clinical implications of recurring chromosomal and associated molecular abnormalities in acute lymphoblastic leukemia.

    abstract::Comprehensive study of the major chromosomal/molecular abnormalities in children and adults with acute lymphoblastic leukemia (ALL) has demonstrated prognostic utility for many of these anomalies, to the extent that cytogenetic and molecular genetic evaluations are now required for optimal clinical management of newly...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(00)90018-0

    authors: Ferrando AA,Look AT

    更新日期:2000-10-01 00:00:00

  • Congenital Defects in the Expression of the Glycosylphosphatidylinositol-Anchored Complement Regulatory Proteins CD59 and Decay-Accelerating Factor.

    abstract::CD59 and decay-accelerating factor (DAF) are glycosylphosphatidylinositol (GPI)-anchored complement regulatory proteins critical for regulating complement activation on the host cell surface. Defective expressions of CD59 or DAF caused by mutations in the genes coding for these proteins or genes involved in the biosyn...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2018.04.004

    authors: Kinoshita T

    更新日期:2018-07-01 00:00:00

  • Monoclonal antibodies in lymphoma: the first decade.

    abstract::The past decade has seen improvements in overall survival (OS) for patients with the two most common lymphoma histologies: diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). In FL, at least four independent datasets have confirmed these survival improvements. The monoclonal antibody rituximab has sign...

    journal_title:Seminars in hematology

    pub_type:

    doi:10.1053/j.seminhematol.2008.02.005

    authors: Link BK,Friedberg JW

    更新日期:2008-04-01 00:00:00

  • Safety profile of recombinant factor VIIa.

    abstract::Recombinant factor VIIa (rFVIIa; NovoSeven(R), Novo Nordisk, Bagsvaerd, Denmark) has been used for many years in the successful management of bleeding episodes in patients with hemophilia and inhibitors. More recently, rFVIIa has also shown considerable success as a hemostatic agent in trauma and surgery patients with...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2003.11.019

    authors: Roberts HR,Monroe DM 3rd,Hoffman M

    更新日期:2004-01-01 00:00:00

  • Mismatched unrelated donor transplantation.

    abstract::There are now more than 25 million volunteer donors registered worldwide for patients in need of a life-saving hematopoietic cell transplant to cure blood disorders. Although a human leukocyte antigen (HLA)-matched donor remains the preferred stem cell source for transplantation, the use of a donor with limited HLA mi...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2016.07.003

    authors: Petersdorf EW

    更新日期:2016-10-01 00:00:00

  • Alternative-donor hematopoietic stem-cell transplantation for severe aplastic anemia.

    abstract::Bone marrow transplantation (BMT) from a human leukocyte antigen (HLA)-matched sibling is the treatment of choice in children and young adults with severe aplastic anemia (SAA). However, because only 30% of patients have a suitable donor, more aggressive nontransplant immunosuppressive regimens have been used, with re...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(00)90029-5

    authors: Margolis DA,Casper JT

    更新日期:2000-01-01 00:00:00

  • Somatic Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.

    abstract::Myeloproliferative neoplasms (MPN) include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). MPN are characterized by clonal proliferation of myeloid progenitors leading to erythrocytosis, thrombocytosis, or leukocytosis, and risk of hemorrhagic and thrombotic events, as well as ...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2018.04.005

    authors: Ferreira Cristina S,Polo B,Lacerda JF

    更新日期:2018-10-01 00:00:00

  • Myelodysplastic syndrome in children and adolescents.

    abstract::Myelodysplastic syndromes (MDS) are clonal disorders characterized by ineffective hematopoiesis and subsequent frequent development of acute myeloid leukemia (AML). In children and adolescents, MDS are uncommon disorders, accounting for less than 5% of hematopoietic malignancy, with great heterogeneity in presentation...

    journal_title:Seminars in hematology

    pub_type: 杂志文章

    doi:10.1053/j.seminhematol.2007.10.006

    authors: Niemeyer CM,Baumann I

    更新日期:2008-01-01 00:00:00

  • The impact of epoetin alfa on quality of life during cancer chemotherapy: a fresh look at an old problem.

    abstract::Untreated anemia is common in cancer patients. Previous studies have demonstrated that both the existence of cancer and treatment with chemotherapy can suppress the normal endogenous erythropoietic response to anemia, making some cancer patients transfusion cadidates. In placebo-controlled phase III studies, administr...

    journal_title:Seminars in hematology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Glaspy J

    更新日期:1997-07-01 00:00:00

  • NK cells as adoptive cellular therapy for hematological malignancies: Advantages and hurdles.

    abstract::Natural killer cells are an essential component of the innate immune system and play a crucial role in immunity against malignancies, without, at difference with T cells, requiring antigen priming or inducing graft-versus-host-disease. Hence, Natural Killer cells can provide a valuable source of allogeneic "off-the-sh...

    journal_title:Seminars in hematology

    pub_type: 杂志文章

    doi:10.1053/j.seminhematol.2020.10.004

    authors: Caruso S,De Angelis B,Carlomagno S,Del Bufalo F,Sivori S,Locatelli F,Quintarelli C

    更新日期:2020-10-01 00:00:00

  • Predictive genetic variants for venous thrombosis: what's new?

    abstract::Various pathways lead to the development of venous thrombosis. Risk factors are common and can be genetic or acquired. Since the identification of factor V Leiden and prothrombin 20210 G-->A, the field of genetic epidemiology has developed rapidly and many new genetic variants have been described in the past decade. H...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2007.01.007

    authors: Bezemer ID,Rosendaal FR

    更新日期:2007-04-01 00:00:00

  • The COP-BLAM programs: evolving chemotherapy concepts in large cell lymphoma.

    abstract::The cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, procarbazine (COP-BLAM) programs of combination chemotherapy were administered to patients with advanced diffuse large cell lymphoma. The original COP-BLAM programs were designed to deliver intense multidrug therapy maximizing tumor kill. COP-BLAM ...

    journal_title:Seminars in hematology

    pub_type: 杂志文章

    doi:

    authors: Coleman M,Armitage JO,Gaynor M,McDermott D,Weisenburger DD,Adler K,Beshevkin M,Silver RT,Reisman AM,Pasmantier MW

    更新日期:1988-04-01 00:00:00

  • New anti-thrombotic agents: emphasis on hemorrhagic complications and their management.

    abstract::Our advanced knowledge of coagulation has led to the synthesis of novel procoagulant substances, such as recombinant activated factor VII (rFVIIa; NovoSeven, Novo Nordisk, Bagsvaerd, Denmark). Similarly, in-depth understanding of the interaction between anticoagulant proteins and their natural inhibitors has led to th...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2005.11.023

    authors: Ng HJ,Crowther MA

    更新日期:2006-01-01 00:00:00

  • Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.

    abstract::The stem cell origination of the clonal process in chronic myeloproliferative disorders (CMPDs) is well established. In chronic myelogenous leukemia (CML), the primary genetic process has been characterized. However, current information regarding the mechanisms of phenotypic diversity among the CMPD and the downstream...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Tefferi A

    更新日期:1999-01-01 00:00:00

  • The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS.

    abstract::The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry enrolls all consecutive patients for whom plasma exchange treatment is requested for clinically diagnosed TTP-HUS within a defined geographic region. During 14.5 years, from January 1, 1989 until June 30, 2003, 301 patients h...

    journal_title:Seminars in hematology

    pub_type: 杂志文章

    doi:10.1053/j.seminhematol.2003.10.001

    authors: George JN,Vesely SK,Terrell DR

    更新日期:2004-01-01 00:00:00

  • Pharmacologic approaches to reversing multidrug resistance.

    abstract::The rationale for modulation of multidrug resistance (MDR) by inhibitors of the multidrug transporter, P-glycoprotein (P-gp) includes the following: (1) P-gp is expressed by human cancers, either at diagnosis or after failure of chemotherapy; (2) P-gp expression at diagnosis has been associated with a poor prognosis i...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Sikic BI

    更新日期:1997-10-01 00:00:00

  • Survival signals in leukemic large granular lymphocytes.

    abstract::The central hypothesis of our laboratory research program in large granular lymphocyte (LGL) leukemia is that leukemic LGL represent antigen-driven cytotoxic T lymphocytes (CTL) with characteristics of dysregulated apoptosis. The clinical features of LGL leukemia highlight the association of autoimmune diseases such a...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(03)00135-5

    authors: Epling-Burnette PK,Loughran TP Jr

    更新日期:2003-07-01 00:00:00

  • Interactions of platelets and endothelial cells with erythrocytes and leukocytes in thrombotic thrombocytopenic purpura.

    abstract::In both normal and abnormal vascular biology, platelet-leukocyte-RBC-EC adhesive and functional interactions appear to play a significant role. The clinical hallmarks of the TTP/HUS syndromes, including prominent platelet aggregation and thrombi without prominent soluble coagulation system activation along with microa...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Smith BR,Rinder HM

    更新日期:1997-04-01 00:00:00

  • Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond.

    abstract::Myelodysplastic syndrome (MDS) with deletion 5q (del(5q)) is a distinct clinical and pathological disease subset that is exquisitely sensitive to lenalidomide for the treatment of red blood cell transfusion-dependent anemia. Although lenalidomide has erythropoeitic promoting activity in MDS without del(5q) (non-del(5q...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2017.06.003

    authors: Talati C,Sallman D,List A

    更新日期:2017-07-01 00:00:00

  • Recombinant factor VIIa (Novoseven) as a hemostatic agent.

    abstract::Recombinant activated factor VII (rFVIIa; NovoSeven, Novo Nordisk, Denmark) induces hemostasis in life- and limb-threatening bleeds and in major surgery of hemophilia A and B patients, regardless of inhibitor titer. A total of more than 6,500 patients have been treated, and NovoSeven has been administered in more than...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(01)90147-7

    authors: Hedner U

    更新日期:2001-10-01 00:00:00

  • Biology of chronic lymphocytic leukemia.

    abstract::Chronic lymphocytic leukemia (CLL) is a clonal proliferation of mature-appearing, but maturationally immature B cells; T cells are rarely involved. Most data suggest that CLL cells are frozen at an early step in maturation; this can be overcome by several techniques such as in vitro incubation with tumor promotors. Al...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Gale RP,Foon KA

    更新日期:1987-10-01 00:00:00

  • Neonatal thrombocytopenia and megakaryocytopoiesis.

    abstract::Thrombocytopenia is common among sick neonates, affecting 20% to 35% of all patients admitted to the neonatal intensive care unit (NICU). While most cases of neonatal thrombocytopenia are mild or moderate and resolve within 7 to 14 days with appropriate therapy, 2.5% to 5% of NICU patients develop severe thrombocytope...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2010.04.002

    authors: Ferrer-Marin F,Liu ZJ,Gutti R,Sola-Visner M

    更新日期:2010-07-01 00:00:00

  • Leukocyte-endothelial cell interactions.

    abstract::Mechanisms that support migration of leukocytes have been studied extensively in vitro. The adhesion of neutrophils under conditions of flow at venous shear rates primarily involves members of the selectin family. E-selectin is upregulated by cytokine stimulation of endothelial cells (ECs); P-selectin is upregulated b...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Smith CW

    更新日期:1993-10-01 00:00:00

  • Somatic characterization of pediatric acute myeloid leukemia using next-generation sequencing.

    abstract::Acute myeloid leukemia (AML) is a complex and heterogeneous disease with distinct age-associated genomic and epigenomic alterations. A large number of somatic karyotypic and molecular alterations have been identified in AML to date; however, very few predict outcome or identify potential therapeutic targets. Here we d...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2013.09.003

    authors: Schuback HL,Arceci RJ,Meshinchi S

    更新日期:2013-10-01 00:00:00

  • Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.

    abstract::Imatinib mesylate (Gleevec, Novartis Pharmaceuticals Corp, East Hanover, NJ; Glivec, Novartis Pharma AG, Basel, Switzerland), a signal transduction inhibitor with preferential effects against the tyrosine kinase activity of the protein product of the ABL proto-oncogene, induced hematologic responses in >or=90% of pati...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/shem.2002.36927

    authors: Hoelzer D,Gökbuget N,Ottmann OG

    更新日期:2002-10-01 00:00:00

  • A rational approach to the diagnosis and management of thrombocytopenia in the hospitalized patient.

    abstract::Thrombocytopenia is one of the most common reasons for inpatient hematology consultations. The main challenges in the management of hospitalized patients with thrombocytopenia are to identify the underlying cause and to recognize when urgent interventions are required. Examination of the blood film is essential in the...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2011.08.002

    authors: Arnold DM,Lim W

    更新日期:2011-10-01 00:00:00